French Drugmaker Sanofi Secures European Medicines Agency's Positive Opinion For Sleeping Sickness Treatment
Portfolio Pulse from Vandana Singh
Sanofi SA (NASDAQ:SNY) received a positive opinion from the EMA's CHMP for Fexinidazole Winthrop, the first oral treatment for acute sleeping sickness (rhodesiense). This treatment is for adults and children over six years old and paves the way for WHO guideline updates and distribution in affected African countries. Sanofi's shares are down 0.62% in premarket trading.
December 15, 2023 | 12:25 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Sanofi's Fexinidazole Winthrop received a positive opinion from the EMA for treating sleeping sickness, which may lead to WHO guideline updates and increased distribution in Africa.
The positive opinion from the EMA is a significant regulatory milestone for Sanofi, likely to lead to increased distribution and sales in African markets where the disease is prevalent. However, the short-term impact on the stock price is neutral to slightly positive, as the premarket dip may be due to broader market conditions or profit-taking rather than a direct response to the news.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100